InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 5,500+ research and publications.
Research title with ★ indicates InBody recommended paper.

Glycemic efficacy and metabolic consequences of an empagliflozin Add-on versus conventional dose-increasing strategy in patient

Shin et al.
Used Parameters : TBW, LBM, BFM, PBF, VFA

Publication Year : 2020

Country : Korea

Journal : Endocrinology and Metabolism

Background We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D). Methods This was a 6-month retrospective case-control study in subjects with uncontrolled T2D (glycated hemoglobin [HbA1c]> 7%) on conventional treatment. The study group started add-on therapy with empagliflozin (10 mg once a day) while the control group was up-titrated with existing medication, using either monotherapy or a combination of metformin …
Full text